Related Experiment Video
Updated: Feb 2, 2026

Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques
Published on: June 1, 2016
Poly(ADP-ribosylated) proteins in β-amyloid peptide-stimulated microglial cells
Virginia Correani1, Sara Martire1, Giuseppina Mignogna1
1Department of Biochemical Sciences, Sapienza University Roma, Italy.
Abstract:
Amyloid-treated microglia prime and sustain neuroinflammatory processes in the central nervous system activating different signalling pathways inside the cells. Since a key role for PARP-1 has been demonstrated in inflammation and in neurodegeneration, we investigated PARylated proteins in resting and in β-amyloid peptide treated BV2 microglial cells. A total of 1158 proteins were identified by mass spectrometry with 117 specifically modified in the amyloid-treated cells. Intervention of PARylation on the proteome of microglia showed to be widespread in different cellular districts and to affect various cellular pathways, highlighting the role of this dynamic post-translational modification in cellular regulation. Ubiquitination is one of the more enriched pathways, encompassing PARylated proteins like NEDD4, an E3 ubiquitine ligase and USP10, a de-ubiquitinase, both associated with intracellular responses induced by β-amyloid peptide challenge. PARylation of NEDD4 may be involved in the recruiting of this protein to the plasma membrane where it regulates the endocytosis of AMPA receptors, whereas USP10 may be responsible for the increase of p53 levels in amyloid stimulated microglia. Unfolded protein response and Endoplasmic Reticulum Stress pathways, strictly correlated with the Ubiquitination process, also showed enrichment in PARylated proteins. PARylation may thus represent one of the molecular switches responsible for the transition of microglia towards the inflammatory microglia phenotype, a pivotal player in brain diseases including neurodegenerative processes. The establishment of trials with PARP inhibitors to test their efficacy in the containment of neurodegenerative diseases may be envisaged.
Insights
Poly(ADP-ribosyl)ation (PARylation) modifies proteins in microglia during amyloid-beta exposure, impacting neuroinflammation. This suggests PARP inhibitors could be potential treatments for neurodegenerative diseases.
Area of Science:
- Neuroscience
- Cell Biology
- Biochemistry
Background:
- Microglia play a crucial role in neuroinflammation within the central nervous system.
- Amyloid-beta peptide triggers inflammatory processes in microglia, contributing to neurodegeneration.
- Poly(ADP-ribosyl)ation (PARP-1) is implicated in inflammatory and neurodegenerative conditions.
Purpose of the Study:
- To investigate the role of PARylation in microglia responding to beta-amyloid peptide.
- To identify specific PARylated proteins and affected pathways in amyloid-treated microglia.
- To explore the potential of PARP inhibitors in neurodegenerative disease treatment.
Main Methods:
- Utilized mass spectrometry to identify and quantify PARylated proteins in BV2 microglial cells.
- Compared protein modification profiles between resting and beta-amyloid peptide-treated cells.
- Analyzed the functional pathways affected by PARylation in microglia.
Main Results:
- Identified 1158 proteins, with 117 specifically PARylated in amyloid-treated microglia.
- PARylation was widespread, affecting diverse cellular compartments and pathways, including ubiquitination, unfolded protein response, and endoplasmic reticulum stress.
- Key proteins like NEDD4 and USP10 were found to be PARylated, suggesting roles in receptor regulation and p53 stabilization.
Conclusions:
- PARylation is a widespread post-translational modification significantly altered in microglia upon amyloid-beta challenge.
- PARylation influences key pathways involved in microglial activation and inflammatory responses.
- Targeting PARP activity with inhibitors may offer a therapeutic strategy for neurodegenerative diseases.
Related Concept Videos
The ADP/ATP Carrier Protein
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Protein and Protein Structure
A protein's shape is critical to its function. For example, an enzyme...
Peptide Bonds
Multi-pass Transmembrane Proteins and β-barrels
α-Helix containing multi-pass transmembrane proteins
Multi-pass transmembrane proteins such as...

